Vladimir Subr

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3168562/publications.pdf

Version: 2024-02-01

79 papers	5,915 citations	87723 38 h-index	71532 76 g-index
80 all docs	80 docs citations	80 times ranked	8465 citing authors

#	Article	IF	Citations
1	Tumor Stimulus-Responsive Biodegradable Diblock Copolymer Conjugates as Efficient Anti-Cancer Nanomedicines. Journal of Personalized Medicine, 2022, 12, 698.	1.1	0
2	Simultaneous Delivery of Doxorubicin and Protease Inhibitor Derivative to Solid Tumors via Star-Shaped Polymer Nanomedicines Overcomes P-gp- and STAT3-Mediated Chemoresistance. Biomacromolecules, 2022, 23, 2522-2535.	2.6	0
3	Singlet Oxygen In Vivo: It Is All about Intensity. Journal of Personalized Medicine, 2022, 12, 891.	1.1	4
4	Metastatic spread inhibition of cancer cells through stimuli-sensitive HPMA copolymer-bound actinonin nanomedicines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 44, 102578.	1.7	0
5	Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. Journal of Controlled Release, 2021, 332, 563-580.	4.8	11
6	Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines. Acta Biomaterialia, 2021, 126, 372-383.	4.1	7
7	The role of the biotin linker in polymer antibody mimetics, iBodies, in biochemical assays. Polymer Chemistry, 2021, 12, 6009-6021.	1.9	3
8	The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody). Journal of Biological Chemistry, 2021, 297, 101342.	1.6	2
9	HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours. Biomaterials, 2020, 235, 119728.	5.7	33
10	Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents. Pharmaceutics, 2019, 11, 343.	2.0	46
11	MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLoS Biology, 2019, 17, e3000354.	2.6	94
12	Singlet oxygen phosphorescence detection in vivo identifies PDT-induced anoxia in solid tumors. Photochemical and Photobiological Sciences, 2019, 18, 1304-1314.	1.6	17
13	Inhibitorâ€“Polymer Conjugates as a Versatile Tool for Detection and Visualization of Cancer-Associated Carbonic Anhydrase Isoforms. ACS Omega, 2019, 4, 6746-6756.	1.6	10
14	Tris-(Nitrilotriacetic Acid)-Decorated Polymer Conjugates as Tools for Immobilization and Visualization of His-Tagged Proteins. Catalysts, 2019, 9, 1011.	1.6	6
15	Identification of Protein Targets of Bioactive Small Molecules Using Randomly Photomodified Probes. ACS Chemical Biology, 2018, 13, 3333-3342.	1.6	9
16	Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxideâ€“Generating Agents Improves the Therapeutic Effects of Nanomedicines. Molecular Cancer Therapeutics, 2018, 17, 2643-2653.	1.9	83
17	N-(2-Hydroxypropyl)methacrylamide-Based Linear, Diblock, and Starlike Polymer Drug Carriers: Advanced Process for Their Simple Production. Biomacromolecules, 2018, 19, 4003-4013.	2.6	22
18	N-(2-hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide-a, a promising tumor-targeted theranostic probe for photodynamic therapy and imaging. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, 165-176.	2.0	36

#	Article	IF	Citations
19	Inhibitor-Decorated Polymer Conjugates Targeting Fibroblast Activation Protein. Journal of Medicinal Chemistry, 2017, 60, 8385-8393.	2.9	21
20	Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate. Biomaterials, 2017, 115, 65-80.	5.7	43
21	Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors. Journal of Controlled Release, 2016, 233, 136-146.	4.8	30
22	Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. Chemical Reviews, 2016, 116, 5338-5431.	23.0	1,333
23	Polymer inhibitors of ABC transporter overcoming multidrug resistance: Synthesis, characterization and in vitro evaluation. Journal of Controlled Release, 2015, 213, e107-e108.	4.8	5
24	Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin. Future Science OA, 2015, 1, FSO4.	0.9	30
25	Traceless Bioresponsive Shielding of Adenovirus Hexon with HPMA Copolymers Maintains Transduction Capacity In Vitro and In Vivo. PLoS ONE, 2014, 9, e82716.	1.1	27
26	Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours. European Journal of Pharmaceutical Sciences, 2014, 58, 1-12.	1.9	65
27	In vivo nanotoxicity testing using the zebrafish embryo assay. Journal of Materials Chemistry B, 2013, 1, 3918.	2.9	104
28	Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound. Journal of the National Cancer Institute, 2013, 105, 1701-1710.	3.0	98
29	Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. Journal of Controlled Release, 2013, 165, 191-198.	4.8	60
30	Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine, 2012, 7, 1683-1695.	1.7	23
31	HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity. Journal of Controlled Release, 2012, 164, 346-354.	4.8	116
32	Removable Nanocoatings for siRNA Polyplexes. Bioconjugate Chemistry, 2011, 22, 169-179.	1.8	12
33	Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. Journal of Controlled Release, 2011, 150, 196-203.	4.8	29
34	Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. Journal of Controlled Release, 2011, 156, 381-389.	4.8	49
35	Low Temperature Aqueous Living/Controlled (RAFT) Polymerization of Carboxybetaine Methacrylamide up to High Molecular Weights. Macromolecular Rapid Communications, 2011, 32, 958-965.	2.0	52
36	Polymer Brushes Showing Nonâ€Fouling in Blood Plasma Challenge the Currently Accepted Design of Protein Resistant Surfaces. Macromolecular Rapid Communications, 2011, 32, 952-957.	2.0	184

#	Article	IF	Citations
37	E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-Î±-activated human umbilical vein endothelial cells. Journal of Drug Targeting, 2011, 19, 690-700.	2.1	10
38	High-molecular-weight Polymers Containing Biodegradable Disulfide Bonds: Synthesis and In Vitro Verification of Intracellular Degradation. Journal of Bioactive and Compatible Polymers, 2010, 25, 5-26.	0.8	19
39	Structural and chemical aspects of HPMA copolymers as drug carriersâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 150-166.	6.6	177
40	Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today, 2010, 5, 197-212.	6.2	126
41	Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells. Tumor Biology, 2010, 31, 233-242.	0.8	18
42	N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. European Journal of Pharmaceutical Sciences, 2010, 41, 473-482.	1.9	120
43	Longâ€Circulating and Passively Tumorâ€Targeted Polymerâ€Drug Conjugates Improve the Efficacy and Reduce the Toxicity of Radiochemotherapy. Advanced Engineering Materials, 2010, 12, B413.	1.6	1
44	HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine, 2010, 5, 1501-1523.	1.7	18
45	Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 514-524.	2.0	42
46	Chemical Conjugation of Cowpea Mosaic Viruses with Reactive HPMA-Based Polymers. Journal of Biomaterials Science, Polymer Edition, 2010, 21, 1669-1685.	1.9	3
47	Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. Journal of Controlled Release, 2009, 135, 152-158.	4.8	52
48	New, Hydrophilic, HPMAâ€Based Polymers for Bioresponsive Shielding of Geneâ€Delivery Vectors. Macromolecular Chemistry and Physics, 2009, 210, 1138-1148.	1.1	6
49	Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials, 2009, 30, 3466-3475.	5.7	219
50	Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009, 113, 1909-1918.	0.6	183
51	Investigation of Nanoparticle Coating by Fluorescence Correlation Spectroscopy. Macromolecular Chemistry and Physics, 2008, 209, 1447-1453.	1.1	5
52	Retargeting polymerâ€coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. Journal of Gene Medicine, 2008, 10, 280-289.	1.4	52
53	Coating of adenoâ€associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. Journal of Gene Medicine, 2008, 10, 400-411.	1.4	55
54	Coating of Vesicles with Hydrophilic Reactive Polymers. Langmuir, 2008, 24, 7092-7098.	1.6	26

#	Article	IF	Citations
55	Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor. Molecular Therapy, 2008, 16, 244-251.	3.7	81
56	Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. Journal of Drug Targeting, 2007, 15, 546-551.	2.1	45
57	Behavior of Surface-Anchored Poly(acrylic acid) Brushes with Grafting Density Gradients on Solid Substrates:â€‰ 1. Experiment. Macromolecules, 2007, 40, 8756-8764.	2.2	252
58	Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. Journal of Controlled Release, 2007, 117, 333-341.	4.8	109
59	Coating of nanoparticles bearing amino groups on the surface with hydrophilic HPMA-based polymers. Colloid and Polymer Science, 2007, 285, 1509-1514.	1.0	10
60	Effect of Intratumoral Injection on the Biodistribution, the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems. Neoplasia, 2006, 8, 788-795.	2.3	103
61	HPMA based macromolecular therapeutics: Internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptidic spacer and also on spacer composition. Journal of Drug Targeting, 2006, 14, 391-403.	2.1	35
62	Synthesis and Characterization of HE-24.8:Â A Polymeric Contrast Agent for Magnetic Resonance Angiography. Bioconjugate Chemistry, 2006, 17, 42-51.	1.8	38
63	Coating of DNA/Poly(l-lysine) Complexes by Covalent Attachment of Poly[N-(2-hydroxypropyl)methacrylamide]. Biomacromolecules, 2006, 7, 122-130.	2.6	62
64	Polymeric Conjugates of 9-[2-(Phosphonomethoxy)ethyl]purine with Potential Antiviral and Cytostatic Activity. Collection of Czechoslovak Chemical Communications, 2006, 71, 1211-1220.	1.0	4
65	Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunology, Immunotherapy, 2006, 56, 35-47.	2.0	57
66	Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. Journal of Controlled Release, 2005, 110, 103-118.	4.8	125
67	Polymeric anticancer drugs with pH-controlled activation. Advanced Drug Delivery Reviews, 2004, 56, 1023-1050.	6.6	464
68	Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. Journal of Controlled Release, 2003, 91, 1-16.	4.8	64
69	Formation and Properties of Anchored Polymers with a Gradual Variation of Grafting Densities on Flat Substrates. Macromolecules, 2003, 36, 2448-2453.	2.2	190
70	Detection and cellular localisation of the synthetic soluble macromolecular drug carrier pHPMA. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1055-1062.	3.3	20
71	Polycationic Graft Copolymers as Carriers for Oligonucleotide Delivery. Complexes of Oligonucleotides with Polycationic Graft Copolymers. Langmuir, 2001, 17, 3096-3102.	1.6	39
72	Poly[N-(2-Hydroypropyl)Methacrylamide] Conjugates of Bovine Seminal Ribonuclease. Synthesis, Physicochemical, and Preliminary Biological Evaluation. Journal of Bioactive and Compatible Polymers, 2000, 15, 4-26.	0.8	8

#	Article	IF	Citations
73	Decreased Binding to Proteins and Cells of Polymeric Gene Delivery Vectors Surface Modified with a Multivalent Hydrophilic Polymer and Retargeting through Attachment of Transferrin. Journal of Biological Chemistry, 2000, 275, 3793-3802.	1.6	148
74	Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin. Bioconjugate Chemistry, 2000, 11, 131-139.	1.8	96
75	Poly[N-(2-hydroxypropyl)meth-acrylamide] Conjugates of Bovine Seminal Ribonuclease. Synthesis, Physicochemical, and Preliminary Biological Evaluation. Journal of Bioactive and Compatible Polymers, 2000, 15, 4-26.	0.8	15
76	Polymeric carriers of drugs for siteâ€specific therapy. Macromolecular Symposia, 1997, 118, 577-585.	0.4	15
77	Evaluation of protein-N-(2-hydroxypropyl) methacrylamide copolymer conjugates as targetable drug-carriers. 2. Body distribution of conjugates containing transferrin, antitransferrin receptor antibody or anti-Thy 1.2 antibody and effectiveness of transferrin-containing daunomycin conjugates against mouse L1210 leukaemia in vivo. Journal of Controlled Release, 1992, 18, 25-37.	4.8	25
78	Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N- (2-hydroxypropyl) methacrylamide copolymers. Journal of Controlled Release, 1991, 16, 121-136.	4.8	65
79	Synthetic Polymers Conjugated to Monoclonal Antibodies: Vehicles for Tumour-Targeted Drug Delivery. Selective Cancer Therapeutics, 1991, 7, 59-73.	0.5	38